指控Ozempic及其他GLP-1类药物导致失明的诉讼案，成为针对该类药物的第二起集体诉讼。
Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs (www.reuters.com) 04:21
PHTI Report 2025: 5 Strategies for Employers to Manage GLP-1 Costs and Coverage
What You Should Know: – The Peterson Health Technology Institute (PHTI) has released a critical purchasing guide for employers struggling to manage the skyrocketing costs of GLP-1 obesity medications. – The report recommends a shift away from broad, unchecked coverage toward a managed approach focused on three phases: Initiation (strict eligibility), Maintenance (adherence support), and […]
With GLP-1 microdoses, Noom targets lower-BMI group outside FDA obesity drug labels
The telehealth company Noom plans to target people with a body mass index well below the requirements for FDA-approved obesity shots, using a microdose GLP-1 offering. The strategy is becoming more common, as online health …
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
Novo Nordisk NVO announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the EU approval of a higher dose of its blockbuster obesity injection, Wegovy (semaglutide). NVO expects a final decision from the European Commission early in 2026. The regulatory filing in the EU seeks […]
GLP-1 medications may Lower Epilepsy Risk in individuals with type 2 diabetes, according to a recent study. Drugs that mimic the action of the hormone glucagon-like peptide-1 (GLP-1) include semaglutide.
submitted by /u/ranjitsingh7 [link] [comments]
Inclusive Sizing Leaders FullBeauty and Destination XL Combine in ‘Merger of Equals’
Destination XL Group (DXL) and FullBeauty Brands, both giants in the big-and-tall/inclusive-sizing category, will combine in a “merger of equals” with combined net sales of $1.2 billion for the year that ended in October 2025. The deal, which has been approved by both companies’ boards, is expected to generate $25 million in annual run-rate cost […]
The GLP-1 effect: How 2026 will look for food and beverage
From shifting grocery habits to new product opportunities, Circana’s insights reveal how brands and retailers can adapt to the rise of GLP-1 users.
Inspire Medical Systems (INSP) Fell Following Reduced Full-Year Guidance
Wasatch Global Investors, an asset management company, released its third-quarter 2025 “Wasatch Small Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. US small-cap equities rallied strongly in the third quarter. The Fed Reserve’s interest rate cut supported the rally. However, the fund-Investor Class struggled to keep up with the […]
Weight Loss Drugs In India: The Rise Of GLP-1s In 2025
GLP-1 receptor agonists mimic the action of the glucagon-like peptide-1 hormone, which is involved in the regulation of appetite and insulin secretion. When administered, these medications stimulate…
‘The role of Ozempic isn’t just about reduced consumption, it’s about a shift in values’
Weight loss medications are quietly reshaping how and why people drink, pushing alcohol towards a more selective and health-aware future. James Bayley asks whether health can be pursued without losing autonomy. The rise of GLP-1 medications such as Ozempic is no longer a background murmur for the drinks trade. It is becoming a decisive force […]